Interleukin 2 receptor antagonists for liver transplant recipients: A systematic review and meta-analysis of controlled studies

Hepatology

Volumn 54, Issue 2, 2011, Pages 541-554

  Goralczyk, Armin D ^a   Hauke, Nicola ^a   Bari, Narin ^a   Y Tsui, Tung ^b   Lorf, Thomas ^a   Obed, Aiman ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; RECEPTOR BLOCKING AGENT; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DEATH; DIABETES MELLITUS; DRUG USE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HYPERLIPOPROTEINEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; META ANALYSIS; NEPHROTOXICITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; STEROID THERAPY; SYSTEMATIC REVIEW; TREATMENT DURATION;

ACUTE DISEASE; CONTROLLED CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; RECEPTORS, INTERLEUKIN-2;

EID: 79960714514     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24385     Document Type: Review

References (46)

1. Asrani SK, Leise MD, West CP, Murad MH, Pedersen RA, Erwin PJ, et al. Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. Hepatology 2010; 52: 1360-1370.
2. OPTN/SRTR Annual Report 2010; 2010. Available from:
3. Pascual J, Marcén R, Ortuño J. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab. Nephrol Dial Transplant 2001; 16: 1756-1760.
4. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 1989; 86: 10029-10033.
5. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997; 350: 1193-1198.
6. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338: 161-165.
7. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77: 166-176.
8. Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2 updated September 2009. The Cochrane Collaboration; 2009. Available from:
9. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
10. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
11. Tippner C, Nashan B, Hoshino K, Schmidt-Sandte E, Akimaru K, Böker KH, et al. Clinical and subclinical acute rejection early after liver transplantation: contributing factors and relevance for the long-term course. Transplantation 2001; 72: 1122-1128.
12. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey SG, Altman DG, eds. Systematic Reviews in Healthcare. 2nd ed. London: BMJ Books; 2001: 285-311.
13. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw 2010; 36( 3).
14. Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis. Stat Med 2007; 26: 37-52.
15. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
16. Bates D, Maechler M. lme4: Linear mixed-effects models using S4 classes. R package version 0.999375-35. 2010. Available at:
17. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
18. Duval SL, Tweedie RL. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 629-634.
19. R Development Core Team (2010). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. Available from:
20. Hu A, He X, Zhu X, Ma Y, Wang G, Wang D, et al. Tacrolimus-based steroid minimization in liver transplantation: A single centre experience. Liver Transplant 2010; 16: S74.
21. Sauer I, Pascher A, Theruvath T, Rau H, Langrehr J, Settmacher U, et al. Basiliximab, tacrolimus and corticosteroids versus tacrolimus and corticosteroids in de novo liver transplant recipients: A prospective randomized study. Abstract from the 2001 Annual Congress of the European Society for Organ Transplantation.
22. Yu Y, Luo XJ, Yi B, Liu C, Jiang XQ. Evaluation of immunosuppressive schemes using non-steroid and early steroid withdrawal in patients following liver transplantation. J Clin Rehab Tissue Eng Res 2010; 14: 803-806.
23. Boillot O, Mayer D, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 2005; 11: 61-67.
24. Calmus Y, Kamar N, Gugenheim J, Duvoux C, Ducerf C, Wolf P, et al. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. Transplantation 2010; 89: 1504-1510.
25. Fasola C, Smallwood G, Martinez E, Steiber A, Heffron T. Daclizumab (DZB) induction in adult hepatitis C (HCV) liver transplant recipients (OLT): a single center experience with different antibody doses. Liver Transpl 2005; 11: C-44.
26. Heffron TG, Smallwood GA, de Vera ME, Davis L, Martinez E, Stieber AC. Daclizumab induction in liver transplant recipients. Transplant Proc 2001; 33: 1527.
27. Humar A, Crotteau S, Gruessner A, Kandaswamy R, Gruessner R, Payne W, et al. Steroid minimization in liver transplant recipients: impact on hepatitis c recurrence and post-transplant diabetes. Clin Transplant 2007; 21: 526-531.
28. Innocenti F, Humeres R, Zamboni M, Sanhueza E, Zapata R, Hepp J, et al. IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile. Transplant Proc 2003; 35: 2520-2521.
29. Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pyrsopoulos N, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007; 84: 829-835.
30. Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007; 13: 1521-1531.
31. Lin CC, Chuang FR, Lee CH, Wang CC, Chen YS, Liu YW, et al. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation. Liver Transpl 2005; 11: 1258-1264.
32. Lu AW, Zheng SS, Wu J, Liang TB, Wang WL, Shen Y, et al. Dual, triple and quadruple oral tacrolimus-based immunosuppression regimens after orthotopic liver transplantation: a randomised comparative study of regimens. Nat Med J China 2006; 86: 3389-3392.
33. Lupo L, Panzera P, Tandoi F, Carbotta G, Giannelli G, Santantonio T, et al. Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: a prospective randomized clinical trial. Transplantation 2008; 86: 925-931.
34. Neuberger J, Mamelok R, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009; 9: 327-336.
35. Neuhaus P, Clavien P, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002; 8: 132-142.
36. Schmeding M, Sauer IM, Kiessling A, Pratschke J, Neuhaus R, Neuhaus P, et al. Influence of basiliximab induction therapy on long-term outcome after liver transplantation, a prospectively randomised trial. Ann Transplant 2007; 12: 15-21.
37. de Simone P, De Carlis L, Filipponi F, Grazi G, Cuomo O, Santaniello W, et al. Results of a multicenter, randomized, open label, controlled clinical trial comparing basiliximab versus steroids in hepatitis C positive liver transplant patients. Transpl Int 2007; 20( Suppl 2): 33.
38. Washburn K, Speeg KV, Esterl R, Cigarroa F, Pollack M, Tourtellot C, et al. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation 2001; 72: 1675-1679.
39. Yan L, Wang W, Li B, Lu S, Wen T. Induction with basiliximab reduces acute rejection in Chinese liver transplant recipients treated with cyclosporin, steroids and MMF. Liver Transpl 2004; 10: C-5.
40. Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005; 11: 1064-1072.
41. Cohen J. coefficient of agreement for nominal scales. Educ Psychol Measure 1960; 20: 37-46.
42. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006; 6: 1578-1585.
43. Farkas SA, Schnitzbauer AA, Kirchner G, Obed A, Banas B, Schlitt HJ. Calcineurin inhibitor minimization protocols in liver transplantation. Transpl Int 2009; 22: 49-60.
44. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
45. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
46. Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of united network for organ sharing registry data. Transplantation 2010; 90: 1511-1515.